ABSTRACT
INTRODUCTION
Extranodal NK/T cell lymphoma, nasal type (ENKCL), recently recognized as a non-Hodgkin's lymphoma (NHL), demonstrates distinct regional and gender differences in the incidence of the disease. It is most commonly found in Asia and South America and quite rare in North America and European countries. It accounts for 2%-10% of all non-Hodgkin's lymphoma. It is more common in men than in women (1, 2) . ENKCL presents unique clinical features, strong invasiveness, rapid progression, high mortality and poor prognosis. Its pathogenesis has not yet been fully understood. There remains disagreement regarding its treatment and prognosis and a lack of effective measures in its prevention and treatment (3, 4) .
Compared with B-cell lymphoma, ENKCL requires more in-depth research, particularly in more precise individualized treatment clinically. This study analyzes the clinicopathological features of ENKCL and discusses the correlation between the pathological factors and the prognosis with literature study in order to provide guidance for clinical treatment.
MATERIALS AND METHODS

Subjects
We collected the clinical and pathological data of 18 
Pathological diagnosis and immunohistochemical detection
Pathological diagnosis was performed using paraffin-embedded sections, hematoxylin and eosin stain and histomorphological examination according to WHO criteria for lymphoid and hematopoietic malignancies (5) . Immunohistochemical staining was conducted using Elivion TM plus method with antibodies and kits purchased from Fuzhou Maixin Company according to the instruction on the kits. PBS, instead of primary antibody, was used for negative control and positive control was designed. In all cases antibody tests were conducted, including CD2, CD3, CD20, CD43, CD56, CD45RO, CD117, CK, BCL-6, GranzymeB, EBER, LCA, TIA-1, Ki-67, etc., and results were analyzed with reference to related literature (6) . Positive CD56 expression showed membrane stained brown yellow or brown and results were classified by color. They were classified into four groups:"-" (no stained cells); "+" (fraction of stained cells <25%); "++" (fraction of stained cells ranged from 25% to 50%); " +++" (fraction of stained cells ≥ 50%). Positive Ki-67 expression showed brown yellow or brown granular precipitate within the nucleus. When observing, we selected 5 high-power fields (400×) in each slice, counted 200 cancer cells in each field and calculated the proportion of positive cells as Ki-67 labeling index (7, 8 45RO and other indicators being positive (9, 10) .
Clinical examination and clinical stage
Clinical examination included a detailed physical examination, endoscopy, imaging, cytological examination of bone marrow, etc. Staging criteria is strictly in accordance with Ann Arbor staging criteria of American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC). B symptoms involved unexplained fever (often body temperature above 38℃) within six months, night sweats and weight loss (of 10% or more).
IPI, including age, tumor stage, ECOG PS score, number of sites of extranodal involvement and serum lactate dehydrogenase level before treatment, was divided into low risk / low-medium risk group (IPI: 0-2) and high-risk group (IPI: 3-5). Short-term efficacy was evaluated using the remission criteria for lymphoma released by International Working Group (IWG) in 1999 and divided into four categories: complete remission (CR), complete remission uncertain (CRu), partial response (PR) and progressive disease (PD).
Follow-up and survival evaluation
Patients were followed up through outpatient service, telephone or letter till June 30, 2012.
The overall survival was the interval between the time of diagnosis and the time of death or last follow-up. Survival evaluation adopted 2-year overall survival (OS) rate after treatment and its correlation with clinicopathological features was studied. Table 1 . 
RESULTS
Basic clinical data
Correlation between lymphocyte phenotype and prognosis
Out of 18 ENKCL cases, 8 had NK cell phenotype and 10 had T cell phenotype, with 2-year OS rates of 100% and 50.0% respectively, which was statistically significant (P = 0.036 <0.05) [ Figure 5 ].
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Correlation between CD 56 expression and prognosis
Immunohistochemical tests found 11 cases of no negative expression and low expression ("+") and 7 cases of moderate ("++") and high expression ("+++"), with 2-year OS rate of 90.9 ％ and 42.9 ％ respectively, suggesting statistically significant difference. Survival curves were shown in Figure 6 . (15, 16) found that drug resistance, absolute lymphocyte counts, β-microglobulin expression, and disease progression are also important independent prognostic indicators. Therefore, some researchers believe that it is necessary to investigate IPI score-independent prognostic factors. Consistent with studies by Lee and Wang et al. (17) , this study also confirmed that Ann Arbor staging, the ECOG PS score, sites of extranodal involvement, presence or absence of bone marrow infiltration, IPI scores, and LDH levels are independent prognostic factors for ENKCL. In addition, our study found that the blood leukocyte count before treatment and the hemoglobin (Hb) level are independent prognostic factors for ENKCL. As early as 1998, Hasenclever et al. (18) that hypoxic cells were insensitive to radiotherapy and chemotherapy and that the poor effects of radiotherapy and chemotherapy in patients with low Hb levels might be related to the low oxygen concentration and increased number of hypoxic cells in the local tumor (20) . The univariate analysis showed that age and sex had no significant effects on survival in this study.
In contrast, others found a positive correlation between age and survival. The difference might result from the different age stratification of the selected subjects in different studies. B symptoms are often considered to be a poor prognostic factor in patients with lymphoma, probably because B symptoms (e.g., unexplained fever and night sweats) are related to an increase in tumor-associated factors (21) . Similar to another study (22) , our study also confirmed that B symptoms were not related to prognosis in ENKCL patients. Therefore, the effects of B symptoms on ENKCL prognosis require further study. The results herein regarding prealbumin concentrations were consistent with previous studies in which the albumin concentration after treatment was not found to be a poor prognostic factor of ENKCL (23) . Furthermore, we found that after the initial course of chemotherapy, radiotherapy, or combination therapy, the 2-year overall survival rate in patients with complete disease remission was significantly increased in comparison to that of patients without complete disease remission, indicating that the efficacy of the initial treatment was important to the prognosis, which was consistent with our conventional understanding (24) .
Similar to the findings of other researchers that drugs such as gemcitabine and L-asparaginase can only reduce the side effects of chemotherapy rather than prolong survival, we found that classification, 18 patients in our study could be divided into 8 NK-cell phenotype cases and 10 T-cell phenotype cases. The 2-year OS rate for the NK-cell phenotype was 100%, which was significantly different from the 50.0% rate for the T-cell phenotype. This finding indicated that the T-cell phenotype had a worse prognosis than did the NK-cell phenotype.
CD56 is a glycoprotein that comprises polypeptide chains and is mainly expressed on the surfaces of NK cells. CD56 also contains polysialic acid units that can form a carbohydrate barrier that reduces contact with the extracellular medium and decreases cell adhesion, which might be associated with tumor invasion. Reportedly, CD56 can lead to the firm adhesion of tumor cells to blood vessel walls, thus damaging the blood vessels, and higher levels of CD56 expression can lead to more aggressive tumor invasion and shorter survival, compared with lower levels of CD56 expression (27) . Anti-CD56 drugs can target tumors by specifically binding to CD56 and might be effective against ENKCL, suggesting that CD56 is important in ENKCL prognosis (28) .
In this study, an immunohistochemical analysis revealed no negative CD56 expression or low expression ("+") in 11 cases and high CD56 expression ("++" or "+++") in 7 cases. Moreover, the 2-year OS rate of the former group was significantly higher than that of the latter, indicating that CD56 should be considered a prognostic indicator for ENKCL.
Ki-67 is a nuclear antigen present in proliferated cells, and its expression is closely related to cell mitosis. Ki-67 expression occurs during the late G1 phase of the cell cycle, increases during the S and G2 phases, peaks during the M phase, and quickly disappears or loses antigenicity post mitosis. Ki-67 is not expressed during DNA repair, has a half-life of only 1 h or shorter, and is considered among the most reliable indicators of tumor cell proliferation of tumor cells but has been classified as a poor prognostic factor by the NCCN (29) . In fact, tumors are usually sensitive to chemotherapy; however, there is a high proportion of proliferated cells with high Ki-67 expression in tumors because of the short doubling time, which can result in a high tumor burden; hence, Ki-67-based prognoses are poor (30) . The univariate analysis herein showed that the survival of patients with low Ki-67 expression levels was significantly longer than that of patients with high Ki-67 expression levels, and the latter group presented with the characteristics of a low remission rate, recurrence, and poor Extranodal NK/T Cell Lymphoma prognosis during ENKCL treatment.
In this study, we included information regarding the rapid development of ENKCL lesions, poor prognosis, Ann Arbor staging, ECOG PS scores, the numbers of sites of extranodal involvement, bone marrow infiltration, IPI scores, white blood cell counts before treatment, Hb levels, LDH levels, first-line treatment effects, CD56 and Ki-67 expression, and lymphocyte phenotypes in 18 patients with ENKCL in a COX proportional hazard model for a multivariate analysis. The results showed that the survival and prognosis of ENKCL patients correlated strongly with the ECOG PS score, number of extranodal involvement sites, IPI score, Hb levels before treatment, LDH levels, first-line treatment effect, CD56 and Ki-67 expression, and lymphocyte phenotype. The analysis indicated that these factors could greatly affect the survival and prognosis of ENKCL patients. Meanwhile, the tumor stage, bone marrow infiltration, and white blood cell counts before treatment also correlated with the survival and prognosis of ENKCL patients, suggesting that these indicators were also important to the survival and prognosis of ENKCL patients.
In summary, the current study regarding the clinicopathological characteristics and prognostic factors of ENKCL could provide valuable information for the development of individualized treatment strategies, especially for refractory and relapsed ENKCL. Hence, the results herein should be verified in future studies with a large number of cases and a long-term follow-up. Given the better understanding of ENKCL clinical pathology-related cell genetics and pathogenesis and the application of gene chip technology, it is hoped that more clinicopathologically significant prognostic indicators for ENKCL can be identified (31, 32) .
